North America’s pharma industry saw a drop of 10.3% in overall deal activity during Q2 2019, when compared to the four-quarter average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 234 deals worth $23.62bn were announced for the region during Q2 2019, against the last four-quarter average of 261 deals.
Of all the deal types, venture financing saw most activity in Q2 2019 with 161, representing a 68.8% share for the region.
In second place was M&A with 58 deals, followed by private equity deals with 15 transactions, respectively capturing a 24.8% and 6.4% share of the overall deal activity for the quarter.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading category in North America’s pharma industry with $19.55bn, while venture financing and private equity deals totalled $2.8bn and $1.27bn, respectively.
North America pharma industry deals in Q2 2019: Top deals
The top five pharma deals accounted for 73.6% of the overall value during Q2 2019.
The combined value of the top five pharma deals stood at $17.38bn, against the overall value of $23.62bn recorded for the quarter. The top announced pharma deal tracked by GlobalData in Q2 2019 was Pfizer’s $11.4bn acquisition of Array BioPharma.
In second place was the $2.2bn acquisition of Peloton Therapeutics by Merck &Inc and in third place was Novartis‘ $1.58bn acquisition of IFM Tre.
The $1.2bn acquisition of Paragon Bioservices by Catalent and Vertex Pharmaceuticals‘ acquisition of Exonics Therapeutics for $1bn held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
